A Phase 3 interventional study of Budesonide in Chronic Obstructive Pulmonary Disease, sponsored by Mahidol University. Completed at 1 site in Thailand. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-09-11.
Sponsored by Mahidol University · Phase 3, Interventional, and Treatment
We hypothesize that ongoing and more severe airway inflammation in COPD may result from the impairment in activation of innate immune response
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 20 is below the median of 72 across 2,118 interventional studies indexed under Lung Diseases.
Browse Lung Diseases studies →Mahidol University is the lead sponsor of 730 studies on the registry; 118 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Postbronchodilator FEV1\> or = 50% predicted
Drug: Budesonide
Postbronchodilator FEV1 \> or = 50% predicted
Drug: Budesonide
Inhaled budesonide 400 mcg twice a day for 2 weeks
Also known as: Rhinocort
Sputum IL-8, IL-17
Time frame: 2 WEEKS
The expression of NF-kappa B in sputum macrophages
Time frame: 2 WEEKS
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mahidol University